This finding is consistent with that of Prakash et al., who showed that vaccines incorporating highly conserved B cell, CD4+, and CD8+ T-cell epitopes induced cross-protection against multiple SARS-CoV-2 variants of concern, significantly reducing severe infection, disease, and mortality. The gene discussed is CD4; the disease is infection.